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Abstract
Background Poor response to diuretics is associated with
worse prognosis in patients with acute heart failure (AHF).
We hypothesized that treatment with tolvaptan improves
diuretic response in patients with AHF.
Methods We performed a secondary analysis of the
AQUAMARINE open-label randomized study in which a
total of 217 AHF patients with renal impairment
(eGFR\ 60 mL/min/1.73 m2) were randomized to either
tolvaptan or conventional treatment. We evaluated diuretic
response to 40 mg furosemide or its equivalent based on
two different parameters: change in body weight and net
fluid loss within 48 h.
Results The mean time from patient presentation to ran-
domization was 2.9 h. Patients with a better diuretic
response showed greater relief of dyspnea and less wors-
ening of renal function. Tolvaptan patients showed a sig-
nificantly better diuretic response measured by diuretic
response based both body weight [-1.16 (IQR -3.00 to
-0.57) kg/40 mg vs. -0.51 (IQR -1.13 to -0.20) kg/
40 mg; P\ 0.001] and net fluid loss [2125.0 (IQR
1370.0–3856.3) mL/40 mg vs. 1296.3 (IQR 725.2–1726.5)
mL/40 mg; P\ 0.001]. Higher diastolic blood pressure
and use of tolvaptan were independent predictors of a
better diuretic response.
Conclusions Better diuretic response was associated with
greater dyspnea relief and less WRF. Early treatment with
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tolvaptan significantly improved diuretic response in AHF
patients with renal dysfunction.
Keywords Acute heart failure  Diuretics  Worsening
renal function  Dyspnea relief
Introduction
Volume overload and subsequent congestion are the pri-
mary causes and treatment targets for acute heart failure
(AHF) [1, 2]. Diuretics have, therefore, been the mainstay
of treatment of patients with AHF [3]. Recent studies,
however, have suggested that there are patients with AHF
who may be refractory to conventional diuretic therapy
[4, 5]. This poor diuretic response is a strong and inde-
pendent predictor of unfavorable prognosis [6], and no
therapy has yet been proven to benefit patients with a poor
diuretic response.
Tolvaptan is an oral, non-peptide, selective vasopressin-
2 receptor antagonist, and prevents the activation of the
aquaporin system and impairs the ability of the kidney to
reabsorb water; as a result, free water excretion is
increased. In the Efficacy of Vasopressin Antagonism in
Heart Failure Outcome Study With Tolvaptan (EVEREST)
trial, tolvaptan showed a favorable short-term effect but
neutral long-term effect in AHF patients [7]. However, in
this trial AHF patients were enrolled relatively late after
presentation as a consequence of inclusion criteria (\48 h
from hospitalization). Recent AHF studies have showed
‘‘time to treatment’’ is a factor associated with drug effi-
cacy and patient prognosis [8, 9] and the latest European
Society of Cardiology heart failure guideline emphasizes
the importance of treating AHF patients as quickly as
possible [10]. Therefore, treatment with tolvaptan in the
very early phase worth evaluating. Moreover, no study has
evaluated diuretic response in Asian AHF patients. In the
AQUAMARINE study (a randomized study evaluated
efficacy of tolvaptan in patients with AHF and renal dys-
function), all patients were randomized within 6 h from
hospitalization. Consequently, median time from first pre-
sentation to randomization was 2.1 h. In this study, we
aimed to evaluate the effect of early treatment with




This is a retrospective secondary analysis of the AQUA-
MARINE study. The study design and primary results of
AQUAMARINE have been described elsewhere [11, 12].
In brief, 217 patients with AHF and renal dysfunction
(estimated glomerular filtration rate, 15–60 mL/min/
1.73 m2) were randomized within 6 h from hospitalization
into two groups, either tolvaptan treatment or conventional
treatment, to evaluate the efficacy of early treatment with
tolvaptan. Fifty-three patients (48.6%) in the tolvaptan
group received tolvaptan for more than 2 days, and no
patient who was initially allocated to conventional group
crossed over to tolvaptan during the first 48 h. The protocol
of the study was approved by the ethics committees of all
participating centers, and written informed consent was
obtained from all the participants. This trial was registered
at UMIN-CTR (Unique identifier: UMIN000007109).
Data collection
In the AQUAMARINE study, data regarding blood pres-
sure, heart rate, and improvement in dyspnea from baseline
and blood samples were collected at 6, 12, 24, and 48 h
from enrollment. Dyspnea was assessed according to the
patient-reported seven-point Likert scale. Within 48 h, the
amount of furosemide-equivalent loop diuretics, change in
body weight from baseline, and urine output were noted
down. Worsening renal function was defined as an increase
of C0.3 mg/dL in the serum creatinine from the baseline at
various pre-specified time points (6, 12, 24, and 48 h from
randomization). The incidence of the combined endpoints
for all-cause mortality and re-hospitalization for heart
failure within 90 days was also evaluated.
Diuretic response
We defined diuretic response as the change in body weight
(kg) from baseline to 48 h per 40 mg intravenous fur-
osemide administration. Oral furosemide was converted to
half the dose of intravenous furosemide. The doses of oral
loop diuretics that were considered equivalent to 40 mg
intravenous furosemide were 10 mg torasemide and 60 mg
azosemide [13, 14]. We also performed analyses using net
fluid loss within 48 h as a measure of diuretic response.
Diuretic response was measured according to body weight
change in 189 cases after excluding 28 cases due to missing
data on the total diuretic dose (n = 3) and body weight
change (n = 25). Data on diuretic response based on net
fluid loss were achieved in 171 cases and missing in 46
cases due to unavailability of information on water intake
in 45 cases and on furosemide dose in 3 cases.
Statistical analysis
Data were expressed as mean ± standard deviation for
normally distributed variables and as median with
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interquartile range (IQR) for non-normally distributed data.
Categorical data were expressed as numbers and percent-
ages. The relationships between baseline characteristics,
outcomes and tertiles of diuretic response were compared
by one-way analysis of variance, Kruskal–Wallis test, or v2
test, as appropriate. Correlation analysis was performed
using Spearman’s rho. When necessary, variables were
transformed for further analyses. Stepwise multiple linear
regression analysis was performed using backward elimi-
nation method after including all variables with P values
below 0.10 in the univariate analysis. Statistical analyses
were performed using R version 3.1.2.
Results
In the AQUAMARINE study, 220 patients were origi-
nally enrolled, of which 217 were analyzed because one
patient in the tolvaptan group and one patient in the
conventional group withdrew their consent and data were
missing for one patient in the tolvaptan group. The
baseline characteristics of randomized patients were
shown elsewhere [12]. The median age of the patients
was 75 years (interquartile range [IQR], 68–81 years),
and 64.9% was male. The median left ventricular ejec-
tion fraction was 44.5%, and 82 (37.8%) patients had a
left ventricular ejection fraction C50%. Mean baseline
eGFR was 40.5 mL/min/1.73 m2, and 57 (26.3%)
patients had an eGFR\ 30 mL/min/1.73 m2. Time from
first-medical record input to randomization was obtained
in 210 (96.8%) patients, and it was 2.9 h in mean, and
2.1 h in median. Time from patient appearance to ran-
domization and the place they appear was shown in
Supplemental Figure 1.
During the first 48 h from study enrollment, the median
administered amount of furosemide-equivalent diuretic
dose was 100 mg (IQR, 62.5–160 mg), median total body
weight change was -2.30 kg (IQR -3.50 to -1.18 kg),
and median net fluid loss was 3973.0 mL (IQR
2566.3–5410.0 mL). The median values for the measures
of diuretic response were -0.83 (IQR -1.50 to -0.40) kg/
40 mg body weight and 1582.8 (IQR 895–2478.3) mL/
40 mg net fluid loss. The baseline characteristics of the
study population according to diuretic response tertiles are
shown in Table 1. Using baseline characteristics, poor
diuretic response based on change in body weight, was
associated with less edematous status, less history of
hypertension, and more hyponatremia. These associations
were retained for diuretic response based on net fluid loss.
In correlation analysis, change in body weight and net fluid
loss showed a statistically significant, but relatively weak
correlation (Spearman’s rho = - 0.47, P\ 0.001) (Sup-
plemental Figure 2).
To identify predictors of diuretic response, univariable
(Supplemental Table 1) and multivariable linear regression
analysis (Table 2) for both parameters were performed.
The only independent predictors of a good diuretic
response for both criteria were tolvaptan use and a higher
diastolic blood pressure. There was no interaction between
baseline diuretics and tolvaptan on diuretic response for
both BW definition (P value for interaction = 0.816) and
net fluid loss definition (P value for interaction = 0.642).
Likewise, no significant interaction was observed between
baseline sodium level, renal function, and impact of
tolvaptan treatment on diuretic response (all P value for
interaction[0.20). For both diuretic response definitions,
no interaction was found on the effect of tolvaptan on
diuretic response between patients who were treated with
and without carperitide (P for interaction = 0.137 with
body weight definition and 0.707 with net fluid loss
definition).
Patients with a poor diuretic response were less likely to
have an improvement in dyspnea relief within 48 h from
randomization, as defined by moderate or marked
improvement from baseline according to the seven-point
Likert scale (Table 3). A poor diuretic response was also
significantly associated with more WRF (Table 3). A
worse diuretic response was not associated with an
increased risk of pre-specified prognostic endpoints within
90 days.
Figure 1 shows the diuretic response according to ran-
domization group, i.e., with and without tolvaptan treat-
ment. Compared to patients who were not treated with
tolvaptan, those who were treated with tolvaptan showed a
significantly better diuretic response based on assessment
by both body weight change [-1.16 (IQR -3.00 to -0.57)
kg/40 mg vs. -0.51 (IQR -1.13 to -0.20) kg/40 mg;
P\ 0.001] and net fluid loss [2125.0 (IQR 1370.0–3856.3)
mL/40 mg vs. 1296.3 (IQR 725.2–1726.5) mL/40 mg;
P\ 0.001].
Discussion
In patients with AHF and renal dysfunction, very early
treatment with tolvaptan was independently associated
with better diuretic response. AHF patients with poor
diuretic response had less dyspnea relief and more fre-
quently experienced worsening renal function.
Diuretic response in AHF
In spite of the lack of a universal definition, poor response
to diuretic therapy has been shown to be one of the most
powerful prognostic predictors in patients with heart failure
[4, 13, 15, 16]. Initial studies used diuretic dose to define
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diuretic response, i.e., patients with persistent heart failure
despite treatment with a certain dose of diuretics were
defined to have a ‘‘poor diuretic response’’ [15, 17].
However, this definition used only amount of diuretics and
hereby obviously ignored response to the diuretics and,
therefore, assumed equal effectiveness. Recently, a novel
definition of diuretic response based on urine/body weight
response to a certain amount of diuretics was proposed [6].
In all studies that evaluated its prognostic potential,
diuretic response consistently showed significant prognos-
tic ability in patients with AHF when this modified defi-
nition was used [4, 5, 18, 19].
There has been no consensus on the parameter used to
measure diuretic response to 40 mg furosemide or its
equivalent, although recent studies have used either change
in body weight, net fluid loss, or total urinary output. In the
present study, we showed relatively poor correlation
between the two measures of diuretic response. This result
was in line with that of the DOSE trial and ASCEND-HF,
which demonstrated a poor agreement between net fluid
loss and weight loss [5, 20]. It is clear that we need better
measures of diuretic response to encompass natriuretic
response, change in volume distribution, and change in
hemodynamic status. However, our consistent results on
the improvement of diuretic response, by two different
parameters, with tolvaptan supported our hypothesis.
According to this novel definition, the median diuretic
response was -0.51 kg/40 mg/48 h furosemide in the
conventional group in our study. This was greater than
approximately 0.4 kg/40 mg of furosemide-equivalent
diuretic response in the patients of the ASCEND-HF
(weight change from admission to 48 h), RELAX-AHF
(weight change from day 1 to 5), and PROTECT (weight
change from day 1 to 4) studies [4, 5, 18]. This better
diuretic response in this AQUAMARINE cohort did not
match our expectations because our study included only
AHF patients with renal dysfunction on admission and
earlier studies suggest that renal dysfunction predisposes to
worse diuretic response [4, 5, 18]. There are several con-
ceivable speculations for this unexpected result. First,
lower doses of loop diuretic were given in AQUA-
MARINE, compared to other studies and the additional
effect of a drug usually decreases at higher doses. Second,
although baseline creatinine values were higher in the
AQUAMARINE cohort than in the ASCEND-HF cohort,
levels of baseline blood urea nitrogen were not substan-
tially different between these two studies. Given that blood
urea nitrogen, but not creatinine, has been suggested by
previous studies as the most powerful determinant of
diuretic response [4, 21], this may be one of the reasons for
discrepancy in our study. Third, median time till random-
ization from patient arrival was 2.1 h and 41.4% of all
AQUAMARINE cohort was randomized before admission
at the emergency department or clinic. This is surprisingly
short given that mean time from admission to randomiza-
tion was 15.5 h in ASCEND-HF and 7.9 h in RELAX-
AHF [22]. This means AQUAMARINE randomized AHF
patients much earlier, and we could, therefore, evaluate
diuretic response in the very early phase which was not
possible with previous diuretic response studies in AHF
cohorts. This difference in the time window might be
associated with the unexpected good diuretic response in
our study cohort. Finally, our results lead to hypothesis that
there may be a racial difference in diuretic response. All of
the studies regarding diuretic response so far predomi-
nantly enrolled Western AHF patients and little is currently
known about diuretic response in Asian AHF patients. This
hypothesis is supported by the observation that the amount
of intravenous loop diuretics used in the acute phase was
very low (around or less than 100 mg/48 h) in Japanese
AHF patients compared to Western patients [12, 23].
Therefore, influence of racial and/or genetic information on
diuretic response needs to be elucidated in future studies.
For both diuretic response parameters, high blood
pressure was associated with a good diuretic response.
These findings were in accordance with the results of
previous studies. In the PROTECT, RELAX-AHF, and
ASCEND-HF cohorts, low diastolic blood pressure was an
independent predictor of poor diuretic response [4, 5, 18].
Interestingly, intravenous unfractionated heparin was
associated with good diuretic response measured with body
weight. We have no clear explanation for this finding;
however, hyperkalemia is known to be a rare but possible
complication of heparin therapy [24], and hypokalemia was
suggested as an independent predictor of poor diuretic
response in PROTECT. Moreover, there is a case report
that suggests a direct effect of heparin on diuresis in
patients with AHF [25]. The association between intra-
venous heparin and diuretic response needs to be precisely
elucidated in the future studies.
Table 2 Multivariable linear regression analysis of diuretic response
Variable Standardized beta t P value
Diuretic response with body weight changes (kg/40 mg furosemide)
Adjusted R2 = 0.214
Tolvaptan treatment -0.339 -5.246 \0.001
Heparin IV -0.241 -3.707 \0.001
DBP -0.149 -2.279 0.024
Edema (moderate/severe) -0.137 -2.088 0.011
Diuretic response with net fluid loss (mL/40 mg furosemide)
Adjusted R2 = 0.176
Tolvaptan treatment 0.387 5.495 \0.001
DBP 0.199 2.854 0.005





















































































































































































































































































































































































































































































































































































































































































































































































































































808 Clin Res Cardiol (2017) 106:802–812
123
Poor diuretic response was significantly associated with
a high incidence of worsening renal function and low rate
of improvement in dyspnea at almost all time points. These
results are in line with the findings of previous studies
[4, 18]; however, it should be acknowledged that the
number of events were very small and this study was
obviously underpowered to evaluate prognostic signifi-
cance of diuretic response.
Effect of tolvaptan on diuretic response
Although some interventions to treat AHF patients with
diuretic resistance have been investigated, there has been
no proven therapy to improve diuretic resistance in this
high risk population. In the ROSE-AHF study, neither low-
dose nesiritide nor low-dose dopamine on top of standard
of therapy was associated with a greater reduction in body
weight within 72 h [26]. Given that the total amount of
furosemide-equivalent diuretic used within 72 h was not
significantly different, neither low-dose dopamine nor low-
dose nesiritide was suggested to improve diuretic response.
Likewise, in ASCEND-HF, nesiritide did not improve
diuretic response [5]. In RELAX-AHF, serelaxin did not
show a significant improvement in diuretic response of
patients with AHF despite its potentially favorable effects
on prognosis [18, 27, 28]. Rolofylline, an adenosine A1-
receptor antagonist, on the other hand did improve diuretic
response [4]. However, its clinical use was hampered by a
neutral effect on prognosis and the concern for
neurological adverse events. Ultrafiltration might be a
promising decongestive strategy [29]; however, it has not
been studied specifically in patients with a poor diuretic
response.
In the present study, we showed that very early treat-
ment with tolvaptan could improve diuretic response in
AHF patients with renal impairment. The pathophysio-
logical background of this favorable effect of tolvaptan on
diuretic response remains to be elucidated; however, it may
be attributed to certain differences in the mechanisms of
action between loop diuretics and tolvaptan. First, time-
dependent diuretic resistance was observed with loop
diuretics. In patients who have been treated with diuretics
for a long time, effectiveness is blunted gradually with time
[30]. Second, loop diuretics have to be bound to plasma
albumin and delivered to the proximal tubules to exert their
effects. Therefore, hypoalbuminemia, which is common in
patients with AHF, could contribute to poor diuretic
response [31, 32]. Third, active secretion of loop diuretics
into the lumen via an organic acid transporter is needed for
them to act [33]. This transporter could be inhibited by
endogenous organic anions [34]. However, compared with
furosemide, tolvaptan has a different mechanism of action,
i.e., inhibiting the activation of vasopressin-2 receptor by
arginine–vasopressin and subsequent insertion of aqua-
porin-2 channels in the collecting tubules. This might be
one of the reasons for the improvement in diuretic response
in renal-impaired patients with AHF after intake of
tolvaptan.
Fig. 1 Diuretic response in
patients with acute heart failure
according to treatment with
tolvaptan. Measurements
compared were a change in
body weight and b net fluid loss
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Contrary to our result, recent sub-analysis from
EVEREST showed a lack of significant difference in pre-
scription rate of tolvaptan between good/bad diuretic
response groups [35]. There are some differences in patient
backgrounds between EVEREST and AQUAMARINE that
possibly explain this discordance (e.g., racial difference,
baseline renal function). However, the most conceivable
explanation for this discrepancy is time to treatment. In
EVEREST, time from hospitalization to dyspnea assess-
ment (the next calendar day after the first drug adminis-
tration) was more than 36 h in 47.7%, and more than 60 h
in 20.2% [36]. In AQUAMARINE about 40% of all
patients were randomized before admission to the hospital
ward and this early capture of AHF patients may lead to
short time to randomization and better diuretic response.
The association between time to therapy and diuretic
response in AHF patient needs to be addressed in future
studies.
Tolvaptan is expected to cause aquaresis but not natri-
uresis. As sodium retention plays a pivotal role in patho-
physiology of AHF, aquaresis may have a different impact
on prognosis from natriuresis in AHF patients. Although
the pathophysiological background of the association
between diuretic response and prognosis has yet to be
elucidated, early successful decongestion and subsequent
symptom relief are plausible mechanisms. Given that
several studies, including AQUAMARINE, have consis-
tently showed urine output with tolvaptan (i.e., aquaresis)
could also lead to decongestion and subsequent symptom
relief, improvement of diuretic response with early treat-
ment with tolvaptan in AHF patients potentially improves
outcome. From this perspective, EVEREST might not be
suitable to evaluate this hypothesis as tolvaptan was used
relatively late and did not improve diuretic response. As we
showed improvement in diuretic response with very early
treatment with tolvaptan for the first time, future studies on
early use of tolvaptan for patients with AHF having poor
diuretic response are warranted.
Our study had several limitations; primarily, its open-
label design, which could have influenced some subjec-
tive prognostic variables, including relief of dyspnea. This
study focused on short-term responses and did not have
sufficient power to detect long term differences in WRF.
We could not address the association between diuretic
response and prognosis because of very little number of
events. As we recruited and randomized patients very
early in our study, some non-AHF patients might have
been included. However, all patients went through careful
clinical history taking, physical examination, chest X-ray
and analysis of natriuretic. Only after confirmation that
patients met the criteria as stated in the protocol, they
were randomized and received the study drug. In addition,
we performed sensitivity analyses comparing the effects
of tolvaptan in patients with a BNP between 100 and
350 pg/ml and above 350 pg/mL We found no interaction
in the effect of tolvaptan on diuretic response in patients
with higher versus lower BNP levels at admission
(P value for interaction = 0.183). No standardized
diuretic regimen was applied and usage of diuretics was
at the discretion of the treating physician. Our findings
regarding association between diuretic response and dys-
pnea relief should be interpreted carefully because base-
line severity of dyspnea was not evaluated and difference
in baseline dyspnea severity between good and poor
diuretic response group might affect difference in degree
of dyspnea relief.
The most powerful limitation of this study which should
be acknowledged is that this is a post hoc and non-pre-
specified analysis. Moreover, several analyses were per-
formed without adjusting for multiple testing. Given these
points, our study result should be interpreted as an
exploratory analysis and hypothesis generating.
Conclusions
Very early treatment with tolvaptan improved diuretic
response in patients with a hospital admission for AHF.
Future research focusing on the prognostic implication of
improving diuretic response with early treatment with
tolvaptan in patients with poor diuretic response is
warranted.
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